APRI on NASDAQ

Apricus Biosciences

Logo: The logo is from the following website: http://www.apricusbio.com, Non-free logo, via Wikipedia4

Apricus Biosciences, Inc. is a San Diego–based biopharmaceutical company advancing innovative medicines in urology and rheumatology.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 16, 2026.

Overview

1987Founded1

Compare with Elicio Therapeutics, Inc., Korsana Biosciences, Inc. or Galmed Pharmaceuticals Ltd., or pick any stock.

  • TickerAPRI on NASDAQ1
  • Industrypharmaceutical industry1
  • HeadquartersSan Diego1
  • Websitewww.apricusbio.com
  • Incorporated inNV5
  • Business address300 Park Avenue, 2Nd Floor, New York, Ny 100225
  • Filer categoryNon-accelerated filer, Smaller reporting company5

See how the biggest companies compare on our leaderboards

Apricus Biosciences, Inc. is a San Diego–based biopharmaceutical company advancing innovative medicines in urology and rheumatology.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-1838.4%Operating margin6
-1719.6%Net margin6

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Research and development100¢$30.1M
  • Interest0¢$75.0K

Out of $2.2M in revenue.6 The company lost money this year.

Financial statements

Revenue7896$2.2M in 2023+331% since 2017
0$1.0M$2.0M$3.0M2017: $511.0K$511.0K20172018: $0$020182019: $375.0K$375.0K20192020: $0$020202023: $2.2M$2.2M2023
Operating income78910116-$40.5M in 2023+279% since 2017
-$80.0M-$60.0M-$40.0M-$20.0M02017: -$10.7M-$10.7M20172018: -$3.2M-$3.2M2018−70%2019: -$29.7M-$29.7M2019+834%2020: -$18.8M-$18.8M2020−37%2021: -$61.7M-$61.7M2021+229%2022: -$70.9M-$70.9M2022+15%2023: -$40.5M-$40.5M2023−43%
Net income78910116-$37.9M in 2023
-$80.0M-$60.0M-$40.0M-$20.0M0$20.0M2017: $321.0K$321.0K20172018: -$3.5M-$3.5M20182019: -$51.3M-$51.3M2019+1375%2020: -$19.1M-$19.1M2020−63%2021: -$66.0M-$66.0M2021+246%2022: -$73.5M-$73.5M2022+11%2023: -$37.9M-$37.9M2023−48%
Fiscal year2017201820192020202120222023
Revenue$511.0K7$08$375.0K9$09$2.2M6
Cost of revenue
Gross profit
Research and development$3.5M7$553.0K8$22.6M9$11.0M10$46.6M11$58.6M6$30.1M6
Operating income-$10.7M7-$3.2M8-$29.7M9-$18.8M10-$61.7M11-$70.9M6-$40.5M6
Interest$131.0K8$29.0K9$164.0K10$1.6M11$14.0K6$75.0K6
Income tax
Net income$321.0K7-$3.5M8-$51.3M9-$19.1M10-$66.0M11-$73.5M6-$37.9M6
Earnings per share-$0.7311-$20.746-$7.736
Earnings per share (diluted)-$0.7311-$20.746-$7.736

Compare Apricus Biosciences with another company

How it started

History

Until September 10, 2010, when it formally changed its name, Apricus Biosciences, Inc. (Nasdaq: APRI) had been operating in the pharmaceutical industry since 1995 under the name NexMed, Inc. NASDAQ:NEXM. On November 15, 2010, Apricus Bio received Canadian approval for its topical ED treatment Vitaros and it announced European approval on June 10, 2013.

In February 2018, the Food and Drug Administration issued its second denial of permission to sell Vitaros in the United States.

From Wikipedia’s article on Apricus Biosciences, shared under CC BY-SA 4.0.3

Former names

  • APRICUS BIOSCIENCES, INC.Sep 8, 2010 to Jan 24, 20195
  • NEXMED INCJun 5, 1997 to Sep 13, 20105

Timeline

  1. Sep 14, 2010Went public Listed on NASDAQ1
  2. 1987Founded Founded1

Recent filings

  1. Nov 22, 20248-K CURRENT REPORT
  2. Oct 24, 20248-K
  3. Oct 15, 20248-K
  4. Oct 7, 20248-K
  5. Sep 26, 20248-K
  6. Sep 25, 2024S-1
  7. Sep 25, 20248-K
  8. Sep 24, 20248-K
  9. Sep 3, 20248-K
  10. Aug 20, 2024DEF 14A
  11. Aug 14, 202410-Q
  12. Aug 8, 20248-K
  13. Jul 26, 20248-K
  14. Jul 16, 20248-K
  15. Jul 12, 20248-K

Every filing from the last three years, summarized. The full record is on SEC EDGAR.2

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14